We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
From clinical trials to clinical practice: How long are drugs tested and then used by patients?
- Authors
Yuan, Chi; Ryan, Patrick B; Ta, Casey N; Kim, Jae Hyun; Li, Ziran; Weng, Chunhua
- Abstract
<bold>Objective: </bold>Evidence is scarce regarding the safety of long-term drug use, especially for drugs treating chronic diseases. To bridge this knowledge gap, this research investigated the differences in drug exposure between clinical trials and clinical practice.<bold>Materials and Methods: </bold>We extracted drug follow-up times from clinical trials in ClinicalTrials.gov and compared the difference between clinical trials and real-world usage data for 914 drugs taken by 96 645 927 patients.<bold>Results: </bold>A total of 17.5% of drugs had longer median exposure in practice than in trials, 6% of patients had extended exposure to at least 1 drug, and drugs treating nervous system disorders and cardiovascular diseases were the most common among drugs with high rates of extended exposure.<bold>Conclusions: </bold>For most of patients, the drug use length is shorter than the tested length in clinical trials. Still, a remarkable number of patients experienced extended drug exposure, particularly for drugs treating nervous system disorders or cardiovascular disorders.
- Subjects
NALTREXONE; DRUG utilization; CLINICAL trials; TRIAL practice; CARDIOVASCULAR diseases; NERVOUS system; DRUGS; RESEARCH funding
- Publication
Journal of the American Medical Informatics Association, 2021, Vol 28, Issue 11, p2456
- ISSN
1067-5027
- Publication type
journal article
- DOI
10.1093/jamia/ocab164